[ad_1]
Labcorp’s latest quarter showed a business that is no longer usefully described through the lens of COVID-era distortion. For the quarter ended March 31, 2026, revenue increased 5.8% year over year to $3.54 billion, while adjusted EPS rose 10.6% to $4.25. Operating cash flow was $191.5 million, up sharply from $18.5 million a year earlier, and free cash flow improved to $70.5 million from negative $107.5 million. Management also raised full-year 2026 guidance, now calling for enterprise revenue growth of 5.0% to 6.1% and adjusted EPS of $17.70 to $18.35.
That matters because the core business mix looks steadier than the old post-pandemic narrative implies. Diagnostics Laboratories generated $2.76 billion of first-quarter revenue, up 5.0%, with 2.9% organic growth and adjusted operating income of $458.7 million. Biopharma Laboratory Services generated $780.6 million of revenue, up 8.2%, including 3.7% organic growth, with adjusted operating income of $120.7 million. Labcorp ended the quarter with $981.1 million of cash and cash equivalents and $6.33 billion of total debt, after pre-funding maturing debt, while still investing $202.2 million in acquisitions, repurchasing $98.0 million of stock, and paying $61.2 million in dividends.
The first reason the story is more durable than a testing-normalization trade is the scale and reach of the diagnostics franchise itself. In the 2025 annual report, Labcorp said its Diagnostics segment generated $10.88 billion of revenue and provides access through more than 2,200 patient service centers and more than 7,000 in-office phlebotomists. That network matters because it makes Labcorp not just a laboratory processor but a workflow partner for physicians, hospitals, and health systems. The company has been explicit that its growth priorities include becoming a partner of choice for health systems and local and regional laboratories, which is a different and more durable thesis than waiting for temporary testing surges.
The second piece of the moat is specialty testing. Labcorp’s filings repeatedly point to oncology, women’s health, autoimmune disease, and neurology as attractive growth areas where advanced diagnostics can support both clinical decision-making and precision medicine. In the first quarter, management highlighted a new Illumina collaboration intended to expand access to genomic testing in oncology and also pointed to broader access for an FDA-approved companion diagnostic tied to Merck’s KEYTRUDA franchise in platinum-resistant ovarian cancer. Those are not commodity-lab markers. They suggest Labcorp is trying to push more of its mix toward harder-to-replicate tests with stronger clinical relevance and stickier provider relationships.
The biopharma-services side makes the overall model even more interesting. In the 2025 annual report, Labcorp said Biopharma Laboratory Services generated $3.10 billion of revenue and supported approximately 85% of the new drugs and therapeutic products approved by the FDA in 2025, including 81% of oncology-related approvals. The company also said those four specialty areas that matter in diagnostics account for more than half of the clinical trials supported by its Central Laboratory business. That creates a useful connection between the two segments: Labcorp can participate in the drug-development workflow on the biopharma side while also building clinical and companion-diagnostic relevance on the diagnostics side.
That linkage helps explain why Labcorp can still grow after the Fortrea separation and the end of COVID comparables. It is not merely shrinking back to a lower baseline. It is operating a two-part model in which diagnostics produces recurring testing volume and cash while biopharma services adds exposure to trial activity, central labs, and early-development work. In 2025, the company generated $13.95 billion of total revenue across those two segments, with Diagnostics contributing about 78% of the mix and Biopharma the rest. The company’s global footprint also matters: Labcorp said its nearly 71,000 employees serve clients in approximately 100 countries and that it performed more than 750 million tests for patients around the world.
There are still risks. Diagnostics growth can be pressured by reimbursement changes, utilization controls, and weather-related volume disruptions, while biopharma services depends partly on sponsor spending and trial timing. Labcorp is also still working through LaunchPad process-improvement initiatives, and some adjusted results exclude restructuring or implementation costs tied to those efforts. Investors should also watch whether acquisition spending and capital returns stay disciplined while debt remains elevated.
Even so, the current shape of the company looks more resilient than the market may give it credit for. A nationwide diagnostics network, growing specialty-test relevance, and a biopharma-lab-services arm that is embedded in clinical-development workflows together create a cash engine that is broader than the old post-COVID testing frame. If Labcorp continues to move mix toward specialty diagnostics and keeps Biopharma Laboratory Services tied to high-value therapeutic activity, the company may prove to be less cyclical and more strategically embedded than the label suggests.
Key Signals for Investors
- First-quarter 2026 results showed growth in both major segments, improved cash generation, and a raised full-year outlook, which is a healthier picture than a simple normalization story.
- Labcorp’s diagnostics moat rests on scale, access, and specialty-test depth, with more than 2,200 patient service centers and more than 7,000 in-office phlebotomists supporting sticky provider workflows.
- The most important strategic question is whether Labcorp can keep linking specialty diagnostics with biopharma and companion-diagnostic activity in a way that sustains mix improvement and cash generation.
Sources
- Labcorp Form 8-K dated April 30, 2026: https://www.sec.gov/Archives/edgar/data/920148/000092014826000135/lh-20260430.htm
- Labcorp first-quarter 2026 earnings release (Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/920148/000092014826000135/form8-kexhibit9911q26.htm
- Labcorp Form 10-Q for the quarter ended March 31, 2026: https://www.sec.gov/Archives/edgar/data/920148/000092014826000139/lh-20260331.htm
- Labcorp Form 10-K for the year ended December 31, 2025: https://www.sec.gov/Archives/edgar/data/920148/000092014826000111/lh-20251231.htm
All figures are GAAP unless otherwise noted.
[ad_2]
Source link